Eribulin Mesylate

證據等級: L5

預測適應症: 0 個

Eribulin Mesylate: Repurposing Evaluation — Prediction Pipeline Incomplete

One-Sentence Summary

Eribulin mesylate (Halaven) is a synthetic halichondrin B analog used as a late-line chemotherapy agent for metastatic breast cancer and liposarcoma. The TxGNN prediction pipeline did not produce any repurposing candidates for this drug in the current run, likely due to upstream data gaps (missing DrugBank ID and original indications) that prevented model execution. No evidence evaluation can be performed until the pipeline is re-run with corrected inputs; this report documents the data gaps and required remediation actions.

Quick Overview

Item	Content
Original Indication	Unable to extract — no approved indication text in the data
Predicted New Indication	No prediction generated (predicted_indications is empty)
TxGNN Prediction Score	—
Evidence Level	L5 (model prediction only) — pending pipeline completion
Canada Market Status	✗ Not Marketed
Number of DINs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

No TxGNN repurposing prediction is available for this drug at this time, so a mechanism-to-indication reasoning cannot be completed.

The DrugBank query recorded in the query log returned one result (result_count: 1, result_status: success), yet the downstream fields drugbank_id, original_indications, and original_moa remain empty or flagged as data gaps. This indicates a pipeline parsing failure rather than a true absence of DrugBank data. Until the DrugBank record is correctly parsed and the prediction model is re-run, mechanistic analysis is premature.

From publicly available sources, eribulin mesylate is a microtubule dynamics inhibitor that suppresses microtubule polymerization at the plus-end, induces G2/M cell cycle arrest, and triggers apoptosis via a mechanism distinct from taxanes and vinca alkaloids. This mechanism is relevant to a broad range of solid tumours, suggesting that repurposing candidates may emerge once the pipeline is unblocked — but this cannot be confirmed without the TxGNN output.

Clinical Trial Evidence

Currently no related clinical trials registered for any predicted new indication — prediction pipeline has not produced a target disease.

Literature Evidence

Currently no related literature available — no target indication to search against.

Canada Market Information

Eribulin mesylate currently holds no Drug Identification Numbers (DINs) in Canada according to this dataset. No license records are available to display.

Note: Eribulin mesylate (Halaven) is approved by the FDA and EMA for metastatic breast cancer and liposarcoma. If Health Canada approval status is confirmed through a direct Health Canada database query, this section should be updated accordingly.

Cytotoxicity

Eribulin mesylate is an antineoplastic agent (halichondrin B analog, microtubule inhibitor). The following is based on the drug class and publicly known safety profile, pending confirmation from the DrugBank record.

Item	Content
Cytotoxicity Classification	Conventional cytotoxic — non-taxane microtubule inhibitor (halichondrin class)
Myelosuppression Risk	High — neutropenia is the primary dose-limiting toxicity; febrile neutropenia reported
Emetogenicity Classification	Low to moderate
Monitoring Items	CBC with differential (weekly in Cycle 1 is typical), liver function, renal function, QT interval (peripheral neuropathy assessment at each cycle)
Handling Protection	Must follow cytotoxic drug handling regulations — closed-system transfer device recommended

Safety Considerations

Safety data (warnings and contraindications) could not be extracted from this Evidence Pack due to data gaps flagged as Blocking severity. Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN pipeline did not produce any repurposing candidates because the DrugBank ID and original indications fields are empty, which are required inputs for the prediction model. Without a target indication, no evidence evaluation, safety-benefit analysis, or regulatory pathway assessment can proceed.

To proceed, the following is needed:

[Blocking — DG001] Retrieve and parse the TFDA/Health Canada product monograph (package insert) to populate key_warnings and contraindications
[High — DG002] Re-query DrugBank API and correctly populate drugbank_id, original_indications, and original_moa — the raw query succeeded (result_count: 1) so this is a parsing issue, not a missing-data issue
[Pipeline] Re-run the TxGNN prediction model once drugbank_id and original_indications are populated; confirm that predicted_indications is non-empty before generating a new report
[Regulatory] Cross-check Health Canada’s Drug Product Database (DPD) directly for any DINs associated with eribulin mesylate, as the current dataset shows zero DINs despite the drug having regulatory approvals in comparable jurisdictions (FDA, EMA)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.